Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Closed 03-05 16:00:00 EST

17.95

-0.66

-3.55%

盘后17.95

+0.000.00%

18:36 EST

High18.70	Low17.66	Vol1.18M
Open18.12	D1 Closing18.61	Amplitude5.59%
Mkt Cap1.37B	Tradable Cap439.35M	Total Shares76.24M
T/O21.26M	T/O Rate4.82%	Tradable Shares24.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":17.95,"timestamp":1772744400000,"preClose":18.61,"halted":0,"volume":1179264,"hourTrading":{"tag":"盘后","latestPrice":17.95,"preClose":17.95,"latestTime":"18:36 EST","volume":17359,"amount":311588.786,"timestamp":1772753797818,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0354648038688877,"floatShares":24476600,"shares":76242800,"eps":0.252426,"marketStatus":"Closed","change":-0.66,"latestTime":"03-05 16:00:00 EST","open":18.12,"high":18.7,"low":17.66,"amount":21256935.26208,"amplitude":0.055884,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.252426,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772787600000},"marketStatusCode":5,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":18.61,"preHourTrading":{"tag":"盘前","latestPrice":18.16,"preClose":18.61,"latestTime":"09:29 EST","volume":625,"amount":11624.12875,"timestamp":1772720999968,"change":-0.45,"changeRate":-0.024181,"amplitude":0.051048},"postHourTrading":{"tag":"盘后","latestPrice":17.95,"preClose":17.95,"latestTime":"18:36 EST","volume":17359,"amount":311588.786,"timestamp":1772753797818,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.993307,"impliedVol":0.5862,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2617648665","title":"Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617648665","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617648665?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:50","pubTimestamp":1772661046,"startTime":"0","endTime":"0","summary":"Markus Warmuth, President and CEO of Monte Rosa Therapeutics, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4VG7q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2616071361","title":"Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616071361","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616071361?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:03","pubTimestamp":1772489004,"startTime":"0","endTime":"0","summary":"Edmund Dunn, Principal Accounting Officer of Monte Rosa Therapeutics, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL52Wjcl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2614804467","title":"Monte Rosa Therapeutics Publishes Corporate Presentation on Molecular Glue Degraders and Targeted Protein Degradation Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614804467","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614804467?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:04","pubTimestamp":1772111084,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Publishes Corporate Presentation on Molecular Glue Degraders and Targeted Protein Degradation Pipeline. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5hW4Dx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2614397710","title":"Monte Rosa Therapeutics (GLUE) Receives a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2614397710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614397710?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:46","pubTimestamp":1772034419,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $37.00. Driscol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/monte-rosa-therapeutics-glue-receives-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/monte-rosa-therapeutics-glue-receives-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2614385390","title":"TD Cowen Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614385390","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614385390?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:56","pubTimestamp":1772027776,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm maintained a Buy rating on Monte Rosa Therapeutics yesterday. The company’s shares closed yesterday at $19.21. Accordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-monte-rosa-therapeutics-glue-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE","COWN","TD"],"gpt_icon":0},{"id":"2614402057","title":"Monte Rosa Therapeutics Chief Medical Officer Filip Janku Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614402057","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614402057?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967151,"startTime":"0","endTime":"0","summary":"Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLwxxPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Monte Rosa Therapeutics Chief Medical Officer Filip Janku Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"gpt_icon":0},{"id":"2613719101","title":"Monte Rosa announces clinical data from Phase 1/2 study of MRT-2359","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719101?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:38","pubTimestamp":1771936692,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combinatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-announces-clinical-data-from-phase-1-2-study-of-mrt-2359-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-announces-clinical-data-from-phase-1-2-study-of-mrt-2359-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","GLUE","BK4230","BK4139","MRT"],"gpt_icon":0},{"id":"2613715421","title":"Monte Rosa to Launch Phase 2 Trial of MRT-2359 Plus AR Inhibitor in AR-Mutant mCRPC in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715421?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:04","pubTimestamp":1771934644,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics announced updated clinical data from an ongoing Phase 1/2 study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated metastatic castration-resistant prostate cancer patients. The company reported that among 15 RECIST-evaluable patients, the overall RECIST disease control rate was 67%, and among five patients with androgen receptor  mutations, the PSA response rate and RECIST disease control rate were both 100%, including two partial responses. The updated results are being presented at the 2026 ASCO Genitourinary Cancers Symposium, with a poster scheduled for February 26, 2026, and the company said it plans to initiate a signal-confirming Phase 2 study in AR-mutant patients in Q3 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9SkXqv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BGHQF748.EUR","BK4539","LU2210149790.SGD","NDAQ","GLUE","BK4588","SG9999014005.SGD","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","SG9999014013.SGD"],"gpt_icon":0},{"id":"2613578900","title":"Monte Rosa Therapeutics to Present at TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613578900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613578900?lang=en_us&edition=fundamental","pubTime":"2026-02-23 20:00","pubTimestamp":1771848042,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLzLslq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210149790.SGD","BK4585","SG9999014013.SGD","EVT.AU","SG9999014005.SGD","GLUE","SG9999014039.USD","BK4139","NDAQ","BK7035","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4539","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2610348961","title":"Monte Rosa Therapeutics Inc Files for Mixed Shelf Offering, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2610348961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610348961?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:39","pubTimestamp":1770845944,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z71JX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2610768806","title":"Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller","url":"https://stock-news.laohu8.com/highlight/detail?id=2610768806","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610768806?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:02","pubTimestamp":1770757343,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Inc. announced that Edmund Dunn will retire from his role as Senior Vice President, Corporate Controller and Principal Accounting Officer, effective April 3, 2026. Matthew Bowen, who has held various finance roles at the company since 2021, will succeed Dunn in these positions. Bowen previously worked at Ernst & Young LLP and is a licensed Certified Public Accountant.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 10, 2026, and is solely responsible for the information contained t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL6T8N9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2604104679","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2604104679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604104679?lang=en_us&edition=fundamental","pubTime":"2026-01-17 09:39","pubTimestamp":1768613940,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Jan. 8 through Jan. 14, 2026. Source: VerityData. Monte Rosa Therapeutics Versant Venture Capital VI reduced its stake in the biotechnology company to 3,250,069 shares. Versant Venture Capital did so through the sale of 597,931 Monte Rosa Therapeutics shares from Nov. 19, 2025, through Jan. 7, 2026, at per share prices ranging from $14.25 to $23.33, and also completed pro rata distributions of 500,030 shares on Dec. 4 and 560,092 shares on Jan. 8. Following the latest activity, Versant Venture Capital continues to own a 4.99% stake in Monte Rosa Therapeutics' outstanding stock, placing Ve","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4149","BK4585","BK4539","BK4548","GLUE","STAA","BK4139","BK4007","BK4588","BK4179","VTOL","ASTE","BK4198"],"gpt_icon":0},{"id":"2603617812","title":"Monte Rosa Therapeutics Price Target Raised to $37.00/Share From $27.50 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2603617812","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603617812?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:59","pubTimestamp":1768402740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 09:59 ET (14:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0},{"id":"2602773309","title":"Monte Rosa Therapeutics CEO Markus Warmuth Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602773309","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602773309?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:06","pubTimestamp":1767992769,"startTime":"0","endTime":"0","summary":"Markus Warmuth, President & CEO of Monte Rosa Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1TtwMk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa Therapeutics CEO Markus Warmuth Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2602137196","title":"BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, home lenders, First Solar","url":"https://stock-news.laohu8.com/highlight/detail?id=2602137196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602137196?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:09","pubTimestamp":1767967794,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, home lenders, First SolarEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nL6N3YA0JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORA","MRK","GM","BK4562","CSIQ","LU0127658192.USD","PIPR","LU0312595415.SGD","LU1935042215.USD","GOOGL","IE00BN29S564.USD","LU1989771016.USD","LU2896262040.SGD","AKAM","FSLR","LU1093756168.USD","LU2125909593.SGD","NEM","LU1242518931.SGD","OKLO","LU0154245756.USD","UWMC","BK4573","TLRY","AXTI","LU0912757837.SGD","VST","LU0642271901.SGD","GLUE","IE00BFSS8Q28.SGD","CRWD","LU1430597077.USD","BK4534","LU2168564222.USD","RKT","AQST","AVGO","LU0345780521.USD","RVMD","ARDX","LU0061474960.USD","LU1267930490.SGD","LU0055631609.USD","LU1069344957.HKD","OPEN","LUV","LU2592432038.USD","LU2211815571.USD","LDI","IE00B5949003.HKD"],"gpt_icon":0},{"id":"2602327045","title":"Monte Rosa Therapeutics 11.125M share Secondary priced at $24.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327045","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602327045?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:15","pubTimestamp":1767957329,"startTime":"0","endTime":"0","summary":"The deal size was increased to $300M in common stock and pre-funded warrants from $200M. Jefferies, TD Cowen and Piper Sandler acted as joint book ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-11-125m-share-secondary-priced-at-24-00-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-11-125m-share-secondary-priced-at-24-00-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","GLUE"],"gpt_icon":0},{"id":"2602457953","title":"Press Release: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2602457953","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602457953?lang=en_us&edition=fundamental","pubTime":"2026-01-09 11:49","pubTimestamp":1767930540,"startTime":"0","endTime":"0","summary":"Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.The shares and pre-funded warrants are being offered by Monte Rosa pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission  on March 20, 2025 and declared effective by the SEC on March 31, 2025 . The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4555","BK4099","BK4139","GLUE","TM","BK4588","BK4539","BK4604","BK4585","USA"],"gpt_icon":0},{"id":"2602975543","title":"Assessing Monte Rosa Therapeutics (GLUE) Valuation After Its Strong 1 Year Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2602975543","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602975543?lang=en_us&edition=fundamental","pubTime":"2026-01-09 02:43","pubTimestamp":1767897816,"startTime":"0","endTime":"0","summary":"Why Monte Rosa Therapeutics Is Drawing Investor Attention\nMonte Rosa Therapeutics (GLUE) has been on investors’ radar after recent trading performance, with the stock showing strong returns over the past month and past 3 months. This has prompted fresh questions about how the current price reflects fundamentals.\nSee our latest analysis for Monte Rosa Therapeutics.\nBeyond the recent spike, Monte Rosa Therapeutics has seen a 131.87% 90 day share price return and a very large 288.65% 1 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/assessing-monte-rosa-therapeutics-glue-valuation-after-its-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/assessing-monte-rosa-therapeutics-glue-valuation-after-its-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4539","GLUE","DCF"],"gpt_icon":0},{"id":"2601360407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360407?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:21","pubTimestamp":1767882071,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, NikeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL6N3Y90NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHOO","RVMD","VNDA","BK4596","SCCO","PHAT","GM","GLUE","BW","LNN","LU0868494708.USD","F","DRI","KTOS","NEM","IE00B4R5TH58.HKD","89988","JCAP","TFX","MPC","HOUS","ABBV","LU0577902298.EUR","TYL","COMP","NOC","APD","VLO","HL","CDE","MLTX","LU0396098781.USD","ALBmain","NEOG","STZ","NKE","HELE","LU2097828805.USD","AA","RTX","LU1267930227.SGD","HBBD.SI"],"gpt_icon":1},{"id":"2601360856","title":"Monte Rosa Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360856","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360856?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:07","pubTimestamp":1767881220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 09:07 ET (14:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":0.0287},{"period":"1month","weight":-0.1087},{"period":"3month","weight":0.0782},{"period":"6month","weight":2.7672},{"period":"1year","weight":2.1812},{"period":"ytd","weight":0.1869}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.6,"avgChangeRate":0.052953},{"month":4,"riseRate":0.25,"avgChangeRate":-0.206735},{"month":5,"riseRate":0.25,"avgChangeRate":-0.009649},{"month":6,"riseRate":0.5,"avgChangeRate":0.041063},{"month":7,"riseRate":0.8,"avgChangeRate":0.071272},{"month":8,"riseRate":0.4,"avgChangeRate":0.098753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction